47-OR: Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: Two-Year Results from the Phase 3 YOSEMITE and RHINE Trials

作者
Carl J. Danzig,John A. Wells,David A. Eichenbaum,Jennifer I. Lim,Kemal Asik,Zdenka Hašková,SHAUN MOHAN,DAVID SILVERMAN,Yannan Tang,HUGH LIN,YOSEMITE AND RHINE INVESTIGATORS
出处
期刊:Diabetes [American Diabetes Association]
卷期号:71 (Supplement_1) 被引量:4
标识
DOI:10.2337/db22-47-or
摘要

Diabetic macular edema (DME) is a major cause of vision loss for people with diabetes. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for DME; however, there is an unmet need for new strategies that address the multifactorial nature of DME, reduce treatment burden, and optimize patient outcomes. Angiopoietin-2 and VEGF-A synergistically drive vascular instability in DME; therefore, dual pathway inhibition with faricimab, the first bispecific antibody designed for intraocular use, may promote vascular stability and durable efficacy beyond current anti-VEGF therapies. YOSEMITE (NCT03622580) and RHINE (NCT03622593) were randomized, double-masked, active comparator-controlled, phase 3 trials designed to assess the efficacy, durability, and safety of faricimab in patients with DME (YOSEMITE, N = 940; RHINE, N = 951) . Patients were randomized 1:1:1 to faricimab 6.0 mg every 8 weeks (Q8W) after 6 initial every-4-week (Q4W) doses, faricimab 6.0 mg per personalized treatment interval (PTI) after 4 initial Q4W doses, or aflibercept 2.0 mg Q8W after 5 initial Q4W doses. The PTI algorithm was a protocol-driven treat-and-extend regimen, with dosing intervals extended, maintained, or reduced (from Q4W up to every 16 weeks [Q16W]) based on prespecified vision and anatomic criteria. Efficacy and safety endpoints were assessed at Q4W study visits through week 100. At 1 year, faricimab Q8W or per PTI offered durable vision gains that were noninferior to aflibercept Q8W and were achieved with Q16W dosing in > 50% of patients in the PTI arms. Faricimab Q8W or per PTI demonstrated anatomic improvements versus aflibercept Q8W and was well tolerated, with low rates of intraocular inflammation. Year 2 results from YOSEMITE/RHINE will be presented at the meeting, and will examine whether early vision gains, anatomic improvements, and extended (up to Q16W) dosing with faricimab are maintained over 2 years. Disclosure C.J. Danzig: Advisory Panel; Genentech, Inc. Consultant; Adverum Biotechnologies, Genentech, Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals Inc. Research Support; Adverum Biotechnologies, Genentech, Inc., Kodiak Pharmaceuticals, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals Inc., Roche Pharmaceuticals. Speaker's Bureau; Novartis Pharmaceuticals Corporation. J.A. Wells: Advisory Panel; Genentech, Inc. Research Support; Adverum, Alimera, Bayer AG, DRCR Retina Network, Genentech, Inc., Gyroscope, Iveric, Kodiak, Lowy Medical institute, Regeneron Pharmaceuticals Inc. D. Eichenbaum: Consultant; Genentech, Inc., Regeneron Pharmaceuticals Inc. Research Support; Bayer AG, Genentech, Inc., Regeneron Pharmaceuticals Inc. Speaker's Bureau; Bayer AG, Genentech, Inc. J.I. Lim: Consultant; Cognition, Eyenuk, Genentech, Inc., Iveric Bio, Novartis AG, Quark, Santen, Luxa, Veridian, Aura, Unity. Research Support; Aldeyra, Chengdu Pharmaceuticals, Regeneron Pharmaceuticals Inc., Stealth, NGM. K. Asik: None. Z. Haskova: Employee; Genentech, Inc. S. Mohan: None. D. Silverman: Employee; Roche Pharmaceuticals. Y. Tang: Employee; Genentech, Inc. H. Lin: Employee; Genentech, Inc. Funding F. Hoffmann-La Roche Ltd. (Basel, Switzerland)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研民工完成签到,获得积分10
刚刚
整齐惋庭完成签到,获得积分10
刚刚
刚刚
1秒前
感性的楷瑞完成签到,获得积分10
1秒前
这朵蘑菇完成签到,获得积分10
1秒前
zz完成签到 ,获得积分10
1秒前
成就歌曲完成签到,获得积分10
1秒前
慕青的应助被tuimao采纳,获得10
2秒前
gcl发布了新的文献求助10
2秒前
2秒前
小王完成签到,获得积分10
2秒前
橘子海完成签到,获得积分10
2秒前
王珑完成签到 ,获得积分10
3秒前
YAOYAO完成签到,获得积分0
3秒前
曹广秀完成签到,获得积分10
3秒前
悲伤的茄子完成签到,获得积分10
3秒前
铁盐君完成签到,获得积分10
3秒前
海的呼唤完成签到,获得积分10
4秒前
西西完成签到,获得积分10
4秒前
WDD完成签到,获得积分10
4秒前
烽火残心完成签到 ,获得积分10
4秒前
Lili发布了新的文献求助30
4秒前
eternal_dreams完成签到 ,获得积分10
5秒前
羊羊完成签到,获得积分10
5秒前
钟贵泉完成签到,获得积分10
5秒前
Fan宝儿完成签到,获得积分10
5秒前
6秒前
xxxxxxxxx完成签到 ,获得积分10
6秒前
6秒前
syx完成签到,获得积分10
7秒前
wyzgood发布了新的文献求助10
7秒前
7秒前
海的呼唤发布了新的文献求助10
7秒前
风筝发布了新的文献求助10
7秒前
劳伦斯完成签到 ,获得积分10
7秒前
明亮元菱完成签到,获得积分10
8秒前
silin完成签到,获得积分10
8秒前
小红完成签到 ,获得积分10
9秒前
敏感的熊猫完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808